Valion Bio develops oral form of radiation countermeasure Entolimod

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to Valion Bio develops oral form of radiation countermeasure Entolimod

Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand

October 9, 2026 7:48 AM EDT

SAN ANTONIO, TX / ACCESS Newswire / October 9, 2026 / As nuclear power assumes an increasingly important role in meeting the growing electricity requirements of artificial intelligence, data centers and other digital infrastructure, the expansion of the U.S. nuclear-energy landscape that has been increasingly making headlines across the country is also highlighting the importance of resilient emergency preparedness and medical countermeasures for potential radiological and nuclear events.

Against this backdrop, Valion Bio, Inc. (Nasdaq: VBIO) ("Valion" or the "Company"), a clinical-stage... More